We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Acurx

News List

ACURX PHARMACEUTICALS Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES firstwordpharma
June 30, 2021
Acurx announced today the closing of its previously announced underwritten initial public offering of 2,875,000 newly-issued shares of common stock, including the full exercise by the underwriters of their option to purchase 375,000 additional shares.
Novel antibiotic shows promise in Phase II C. difficile study europeanpharmaceuticalreview
November 23, 2020
Ibezapolstat cured all 10 patients of their Clostridioides difficile infections and prevented recurrence for at least 30 days.
Acurx Successfully Completes Ph1 Clinical Trial for ACX-362E in CDI americanpharmaceuticalreview
September 03, 2019
Acurx Pharmaceuticals announced its lead product candidate, ACX-362E, has successfully completed the 68-subject, double-blind, placebo-controlled, multiple-ascending dose Phase 1 clinical trial of ACX-362E in healthy volunteers.